Approximately 24 million people around the world live with schizophrenia, a serious, chronic mental health disorder that causes distortions in thinking, perceptions, emotions, and behavior.
Most people living with schizophrenia experience only partial improvement or undesirable side effects with their current treatments, resulting in a significant economic impact owing to direct and indirect costs – including those associated with caregiving.
Approximately 24 million people around the world live with schizophrenia.
J&J’s approach to schizophrenia
Our longstanding commitment to developing innovative treatments for schizophrenia began in the late 1950s, when we introduced a therapy that revolutionized the treatment paradigm for the disorder. Today, our portfolio includes multiple long-acting injectable treatments with a range of dosing schedules designed to support symptom control and treatment goals for people living with schizophrenia.
